University Health Network-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Annals of the Rheumatic Diseases

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 75, Núm. 5, pp. 998-1006

  3. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 7, pp. 927-936

2022

  1. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 11, pp. 1541-1548

2020

  1. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

2019

  1. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159

  2. Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort

    Arthritis Care and Research, Vol. 71, Núm. 7, pp. 893-902

  3. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort

    Annals of the Rheumatic Diseases

  4. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen

    Rheumatology (United Kingdom), Vol. 58, Núm. 7, pp. 1259-1267

  5. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort

    Rheumatology (United Kingdom), Vol. 57, Núm. 4, pp. 677-687

2017

  1. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

  2. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

    Lupus, Vol. 26, Núm. 10, pp. 1051-1059

2015

  1. Anti-C1q antibodies in systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 1, pp. 42-49

2012

  1. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2677-2686